{"disease":{"id":"fibrodysplasia-ossificans-progressiva","name":"fibrodysplasia ossificans progressiva"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04665323","title":"An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.","phase":"","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT06064656","title":"A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)","phase":"","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT02322255","title":"A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Clementia Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT05039515","title":"A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":113,"lead_sponsor_name":"Clementia Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03312634","title":"An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Clementia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT06089616","title":"A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT05090891","title":"To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06508021","title":"A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":92,"lead_sponsor_name":"Ashibio Inc","has_results":false},{"nct_id":"NCT05394116","title":"A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":63,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05027802","title":"A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT02279095","title":"An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Clementia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04829773","title":"Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Clementia Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04818398","title":"Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Daiichi Sankyo Co., Ltd.","has_results":false},{"nct_id":"NCT03188666","title":"A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT02190747","title":"An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Clementia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04307953","title":"Saracatinib Trial TO Prevent FOP","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT02521792","title":"In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Clementia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT07301450","title":"An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)","phase":"","overall_status":"TEMPORARILY_NOT_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}